Title
Category
Credits
Event date
Cost
- Alzheimer Disease
- Dementia
- Integrated Care
- Neuroimaging
- Patient/Physician Communication
- Primary Care
- AMA PRA Category 1 Credit™
- Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- AMA PRA Category 1 Credit™
- Participation
$0.00
Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- AMA PRA Category 1 Credit™
- Participation
$0.00
Among the most transformative Alzheimer Disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.